-
SHC-1 Inhibition and CFTR Surface Abundance
2026-09-26
This study tests whether SHC-1-dependent CFTR internalization operates across airway and intestinal epithelial models, finding that the pathway is detectable in multiple cell lines but inhibitor-associated increases in surface CFTR are limited to CFBE cells. Because those increases coincided with changes in other membrane proteins, the results highlight cell-model dependence and the need to distinguish CFTR trafficking effects from broader changes in plasma membrane abundance.
-
AEBSF.HCl in Necroptosis: Read the Protease Class
2026-09-25
AEBSF.HCl is an irreversible serine protease inhibitor, but it is not a direct test of cathepsin B activity in necroptosis. This article connects its established research uses with lysosomal membrane permeabilization findings to clarify what the compound can—and cannot—tell you in cell-death assays.
-
Resazurin Sodium Salt in iPSC Drug Testing
2026-09-25
Use Resazurin sodium salt as a fast metabolic readout alongside—not instead of—CFTR function assays in cystic fibrosis iPSC models. This guide covers practical plate workflows, pilot conditions, and controls that help distinguish treatment-related toxicity from changes in cellular metabolism.
-
Psoralen-Induced Cholestasis via ERK1/2 Activation
2026-09-24
A 2024 zebrafish study links the estrogen-like effects of psoralen and isopsoralen to cholestatic liver injury and increased ERK1/2 phosphorylation. Its combination of estrogen-response markers, liver-function phenotyping, gene-expression analysis, and inhibitor-based rescue makes ERK1/2 a testable contributor to phytoestrogen-associated cholestasis, while leaving important questions about causality and human relevance open.
-
From CFTR Blockade to Trafficking Biology
2026-09-24
CFTR research benefits from separating channel activity from the number of channels at the epithelial surface. This article connects the rapid, reversible action of CFTRinh-172 with new findings on SHC-1-dependent CFTR trafficking—and offers a translational framework for designing experiments that distinguish these mechanisms.
-
SCH772984 HCl: ERK Inhibition Beyond Tumor Growth
2026-09-23
SCH772984 HCl is a potent ERK1/2 inhibitor for probing MAPK signaling and cancer biology. This article connects ERK perturbation to emerging evidence on TERT regulation, with a practical framework for distinguishing kinase engagement from epigenetic and cell-state effects.
-
Magneto-Piezoelectric Scaffolds for Infected Bone Repair
2026-09-23
Wu et al. developed a dual-responsive, 3D-printed scaffold that combines magnetic biofilm disruption with ultrasound-mediated metabolic activation of Icam1+ macrophages. The study links JAK2-STAT3-dependent oxidative phosphorylation to improved immune support for bone regeneration after infection control.
-
Bifendate (DDB): Mechanism to Assay Design
2026-09-22
Bifendate (DDB) is a hepatoprotection agent with linked effects on lipid metabolism, autophagy, and CYP3A4-dependent pharmacokinetics. This guide translates those mechanisms into better assay design, interpretation, and translational risk assessment.
-
Repaglinide as a Metabolic Control in DNA Repair Studies
2026-09-22
Repaglinide is best understood here as a controlled metabolic perturbation, not a direct ATG4B inhibitor. This article translates recent energy deficiency–DNA repair findings into practical assay design and interpretation strategies.
-
U0126-EtOH: A Pathway-Logic Guide
2026-09-21
U0126-EtOH is a selective MEK1/2 inhibitor for resolving how ERK signaling shapes neuronal injury, inflammation, and differentiation. This guide focuses on assay logic, pathway-specific interpretation, and the critical distinction between MEK1/2 and parallel ERK5 signaling.
-
Torin2: A Causal Assay Framework for mTOR
2026-09-21
Torin2 is a potent mTOR inhibitor for dissecting pathway suppression from cell-death execution. This article presents an assay framework that connects mTOR pharmacology, Pol II degradation, and interpretation of apoptosis data in cancer research.
-
Deferoxamine: Mapping Iron-Dependent Cell Death
2026-09-20
Deferoxamine and DeferoxamineB provide a mechanistically useful iron-chelation axis for separating ferroptosis from apoptosis, autophagy, and copper-associated stress. This article develops a causal assay framework that complements recent metabolic nanomedicine findings rather than simply repeating protocol guidance.
-
Gepotidacin (GSK2140944) Research Workflows
2026-09-19
Build reliable antibacterial assays around Gepotidacin’s distinct bacterial topoisomerase mechanism, from broth microdilution to DNA-cleavage and target-engagement studies. This practical guide also shows how lessons from pathway-regulation research can improve controls, assay interpretation, and antibiotic resistance research.
-
Deferoxamine Mesylate: Iron Chelation Guide
2026-09-18
Deferoxamine mesylate is an iron-chelating agent used to reduce chemically available iron in research models. Product information supports applications in oxidative stress protection, HIF-1α stabilization, wound healing promotion, and model-specific tumor studies.
-
H-151 Suppresses Ferroptosis via Radical Trapping
2026-09-18
Yin et al. report that the STING inhibitor H-151 suppresses ferroptosis through a second, STING-independent activity: radical trapping that limits Fenton chemistry and lipid peroxidation. In a murine renal ischemia-reperfusion injury model, this dual action reduced tissue damage and improved renal function, highlighting coordinated control of inflammation and ferroptosis as a therapeutic strategy.